Peter Howarth
Affiliations: | 1985-1989 | Vision Sciences | University of California, Berkeley, Berkeley, CA, United States |
Google:
"Peter Howarth"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yasinska V, Gómez C, Kolmert J, et al. (2023) Low levels of endogenous anabolic androgenic steroids in females with severe asthma taking corticosteroids. Erj Open Research. 9 |
| Liu MC, Bagnasco D, Matucci A, et al. (2023) Mepolizumab in patients with severe asthma and comorbidities: 1-year REALITI-A analysis. The Journal of Allergy and Clinical Immunology. in Practice |
| Siddiqui S, Bachert C, Bjermer L, et al. (2023) Eosinophils and tissue remodeling: relevance to airway disease. The Journal of Allergy and Clinical Immunology |
| Zeng X, Qing J, Li CM, et al. (2023) Blood transcriptomic signature in type-2 biomarker low severe asthma and asthma control. The Journal of Allergy and Clinical Immunology |
| Versi A, Ivan FX, Abdel-Aziz MI, et al. (2023) Haemophilus influenzae and Moraxella catarrhalis in sputum of severe asthma with inflammasome and neutrophil activation. Allergy |
| Pavord I, Gardiner F, Heaney LG, et al. (2023) Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Frontiers in Immunology. 14: 1150162 |
| Kroes JA, Alfonso-Cristancho R, Bansal AT, et al. (2023) Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis. Erj Open Research. 9 |
| Eastwood MC, Busby J, Jackson DJ, et al. (2023) A randomised trial of a T2-composite-biomarker strategy adjusting corticosteroidtreatment in severe asthma, a post- hoc analysis by sex. The Journal of Allergy and Clinical Immunology. in Practice |
| Casale TB, Burnette A, Bourdin A, et al. (2022) Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies. Therapeutic Advances in Respiratory Disease. 16: 17534666221107313 |
| Pilette C, Canonica GW, Chaudhuri R, et al. (2022) REALITI-A study: Real-world oral corticosteroid-sparing effect of mepolizumab in severe asthma. The Journal of Allergy and Clinical Immunology. in Practice |